A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
Interventions
- DRUG: Efimosfermin
- DRUG: Placebo
Sponsor
Boston Pharmaceuticals
Collaborators